查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1274353

特发性血小板减少性紫癜治疗全球市场研究报告——2023-2030 年行业分析、规模、份额、增长、趋势和预测

Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
出版日期: | 出版商: Value Market Research | 英文 123 Pages | 商品交期: 最快1-2个工作天内

价格

2023-2030 年研究期间，全球对特发性血小板减少性紫癜治疗市场的需求将以 8.52% 的复合年增长率增长，从 2022 年的 7.0059 亿美元增长到 2030 年的近 13.4754 亿美元 预计将达到美元市场规模.

特发性血小板减少性紫癜 (ITP) 是一种自身免疫性疾病，会导致血液中血小板数量减少。 血小板是血液正常凝结所必需的，血小板数量少会导致出血过多和瘀伤。 ITP 疗法是指用于管理和治疗特发性血小板减少性紫癜的药物、疗法和医疗器械。

市场动态：

由于人口老龄化和自身免疫性疾病增加等因素，ITP 在世界范围内的患病率正在上升。 这推动了 ITP 治疗市场的需求。 ITP 疗法的技术进步，例如生物製剂的开发，正在改善治疗效果并推动市场增长。 世界各国政府正在提供财政支持和激励措施，以加速 ITP 疗法的开发和采用，从而推动市场增长。 随着越来越多的人寻求有效治疗，对 ITP 及其治疗的认识不断提高，推动了对 ITP 治疗的需求。 儘管有一些治疗方法可用，但对更有效和负担得起的 ITP 疗法的未满足需求仍然很高，这推动了对新疗法和改进疗法的需求。 单克隆抗体等生物製剂市场的扩大以及这些药物作为 IT□□P 治疗药物的日益普及有望推动 ITP 治疗药物市场的增长。 保险公司对 ITP 药物的承保使 ITP 患者更容易获得和负担得起这些药物，从而推动了对这些药物的需求。

这份研究报告解释了波特的五力模型、市场吸引力分析和价值链分析。 这些工具可帮助您清楚地了解您的行业结构并评估您在全球范围内的竞争吸引力。 此外，这些工具还可以全面评估全球特发性血小板减少性紫癜市场的每个部分。 特发性血小板减少性紫癜药物行业的发展和趋势为这项研究提供了一个整体方法。

市场细分：

特发性血小板减少性紫癜治疗市场报告的这一部分提供了国家/地区级别的细分市场的详细数据，从而帮助战略家针对人口统计数据和他们各自产品或服务的即将到来的机会。帮助确定

按产品

  • 肾上腺皮质类固醇
  • 用于静脉滴注免疫球蛋白
  • 抗D免疫球蛋白
  • TPO-RA

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲、中东和非洲特发性血小板减少性紫癜市场当前和未来的需求。 此外，它还关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的综合概况和全球竞争格局的详细视图。 特发性血小板减少性紫癜治疗市场的主要参与者是 Hoffman-L Roche、Amgen Inc、Grifols Biologicals Inc、GlaxoSmithKline Plc 等。 本节概述了竞争格局，包括各种战略发展，例如主要併购、未来能力、合作伙伴关係、财务概览、联合研究、新产品开发和新产品发布。

如果您有定制要求，请联繫我们。 我们的研究团队可以根据您的需要提供定制报告。

内容

第一章前言

  • 本报告的内容
    • 目的
    • 目标受众
    • 独特的销售主张 (USP) 及其提供的内容
  • 调查范围
  • 调查方法
    • 市场调研过程
    • 市场研究方法

第 2 章执行摘要

  • 市场亮点
  • 全球市场概况

第3章特发性血小板减少性紫癜药物产业分析

  • 简介 - 市场动态
  • 市场驱动力
  • 市场製约因素
  • 市场机会
  • 行业趋势
  • 波特的五力分析
  • 市场吸引力分析
    • 市场吸引力分析：按产品
    • 市场吸引力分析：按地区

第四章价值链分析

  • 价值链分析
  • 原材料分析
    • 原材料清单
    • 原材料製造商列表
    • 主要原材料价格走势
  • 潜在买家名单
  • 营销渠道
    • 直接营销
    • 间接营销
    • 营销渠道趋势

第 5 章 COVID-19 爆发的影响分析

第 6 章特发性血小板减少性紫癜药物的全球市场分析：副产品

  • 产品概览
  • 实际数据和预测数据
  • 按产品分析
  • 肾上腺皮质类固醇
  • 静脉注射免疫球蛋白疗法
  • 抗D免疫球蛋白
  • TPO-RA

第7章特发性血小板减少性紫癜药物的全球市场分析：按地区

  • 区域展望
  • 简介
  • 北美销售分析
    • 概览、历史和预测销售分析
    • 北美各部门的销售分析
    • 北美销售分析
    • 美国销售分析
    • 加拿大销售分析
    • 墨西哥销售分析
  • 欧洲销售分析
    • 概览、历史和预测销售分析
    • 按细分市场进行的欧洲销售分析
    • 按国家/地区划分的欧洲销售分析
    • 英国销售分析
    • 法国销售分析
    • 德国销售分析
    • 意大利销售分析
    • 俄罗斯销售分析
    • 其他欧洲销售分析
  • 亚太地区销售分析
    • 概览、历史和未来销售分析
    • 亚太地区各部门的销售分析
    • 亚太国家/地区销售分析
    • 在中国的销售分析
    • 印度销售分析
    • 日本的销售分析
    • 韩国销售分析
    • 澳大利亚销售分析
    • 其他亚太地区销售分析
  • 拉丁美洲销售分析
    • 概览、历史和未来销售分析
    • 拉丁美洲各部门的销售分析
    • 拉丁美洲国家/地区的销售分析
    • 巴西销售分析
    • 阿根廷销售分析
    • 秘鲁销售分析
    • 智利的销售分析
    • 其他拉丁美洲销售分析
  • 中东和非洲销售分析
    • 概览、历史和未来销售分析
    • 中东/非洲地区的销售分析
    • 中东和非洲国家/地区的销售分析
    • 沙特阿拉伯销售分析
    • 阿联酋销售分析
    • 以色列销售分析
    • 南非销售分析
    • 其他中东和非洲销售分析

第8章：特发性血小板减少性紫癜药物企业竞争格局

  • 治疗特发性血小板减少性紫癜药物的市场竞争
  • 伙伴关係/协作/协议
  • 併购
  • 新产品发布
  • 其他发展

第九章公司简介

  • 顶级公司的市场份额分析
  • 市场集中度
  • Hoffman-L Roche
    • 公司简介
    • 企业收入
    • 产品介绍
    • 近期发展状况
  • 安进公司
    • 公司简介
    • 企业收入
    • 产品信息
    • 近期发展状况
  • Grifols Biologicals Inc.
    • 公司简介
    • 企业收入
    • 产品信息
    • 近期发展状况
  • 葛兰素史克公司。
    • 公司简介
    • 企业收入
    • 产品信息
    • 近期趋势

注意：公司简介中的财务细节和近期发展基于可用信息，可能不包括私营公司。

Product Code: VMR112110446

The global demand for Idiopathic Thrombocytopenic Purpura Therapeutics Market is presumed to reach the market size of nearly USD 1347.54 MN by 2030 from USD 700.59 MN in 2022 with a CAGR of 8.52% under the study period 2023 - 2030.

Idiopathic thrombocytopenic purpura or ITP is an autoimmune disorder that leads to a low platelet count in the blood. Platelets are necessary for proper blood clotting, and its low count can cause excessive bleeding and bruising. ITP therapeutics refers to the drugs, treatments, and medical devices used to manage and treat idiopathic thrombocytopenic purpura 

Market Dynamics:

The prevalence of ITP is increasing globally due to factors such as ageing populations and a rise in autoimmune disorders. This is driving demand for ITP therapeutics market. Technological advancements in ITP therapeutics, such as the development of biological drugs, are improving treatment outcomes and driving the market growth. Governments around the world are providing financial support and incentives to promote the development and adoption of ITP therapeutics, driving the market growth. Increasing awareness about ITP and its treatment options is driving demand for ITP therapeutics as more individuals seek out effective treatment options. Despite the availability of some treatments, there is still a high unmet need for more effective and affordable ITP therapeutics, driving demand for new and improved treatments. The growing market for biologics, including monoclonal antibodies and other biologic drugs, is expected to drive the growth of the ITP therapeutics market as these drugs become increasingly popular for treating ITP. Insurance companies are providing coverage for ITP therapeutics, making them more accessible and affordable for individuals with ITP, which is driving demand for these treatments.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of idiopathic thrombocytopenic purpura therapeutics. The growth and trends of idiopathic thrombocytopenic purpura therapeutics industry provide a holistic approach to this study. 

Market Segmentation:

This section of the idiopathic thrombocytopenic purpura therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities. 

By Product

  • Corticosteroids
  • Intravenous Immunoglobulin
  • Anti-D Immunoglobulin
  • TPO-RA

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Idiopathic Thrombocytopenic Purpura Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the idiopathic thrombocytopenic purpura therapeutics market include Hoffman-L Roche, Amgen Inc, Grifols Biologicals Inc., and GlaxoSmithKline Plc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . IDIOPATHIC THROMBOCYTOPENIC PURPURA THERAPEUTICS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Product
    • 3.7.2 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL IDIOPATHIC THROMBOCYTOPENIC PURPURA THERAPEUTICS MARKET ANALYSIS BY PRODUCT

  • 6.1 Overview by Product
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Product
  • 6.4 Corticosteroids Historic and Forecast Sales by Regions
  • 6.5 Intravenous Immunoglobulin Historic and Forecast Sales by Regions
  • 6.6 Anti-D Immunoglobulin Historic and Forecast Sales by Regions
  • 6.7 TPO-RA Historic and Forecast Sales by Regions

7 . GLOBAL IDIOPATHIC THROMBOCYTOPENIC PURPURA THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

  • 7.1. Regional Outlook
  • 7.2. Introduction
  • 7.3. North America Sales Analysis
    • 7.3.1. Overview, Historic and Forecast Sales Analysis
    • 7.3.2. North America By Segment Sales Analysis
    • 7.3.3. North America By Country Sales Analysis
    • 7.3.4. United State Sales Analysis
    • 7.3.5. Canada Sales Analysis
    • 7.3.6. Mexico Sales Analysis
  • 7.4. Europe Sales Analysis
    • 7.4.1. Overview, Historic and Forecast Sales Analysis
    • 7.4.2. Europe by Segment Sales Analysis
    • 7.4.3. Europe by Country Sales Analysis
    • 7.4.4. United Kingdom Sales Analysis
    • 7.4.5. France Sales Analysis
    • 7.4.6. Germany Sales Analysis
    • 7.4.7. Italy Sales Analysis
    • 7.4.8. Russia Sales Analysis
    • 7.4.9. Rest Of Europe Sales Analysis
  • 7.5. Asia Pacific Sales Analysis
    • 7.5.1. Overview, Historic and Forecast Sales Analysis
    • 7.5.2. Asia Pacific by Segment Sales Analysis
    • 7.5.3. Asia Pacific by Country Sales Analysis
    • 7.5.4. China Sales Analysis
    • 7.5.5. India Sales Analysis
    • 7.5.6. Japan Sales Analysis
    • 7.5.7. South Korea Sales Analysis
    • 7.5.8. Australia Sales Analysis
    • 7.5.9. Rest Of Asia Pacific Sales Analysis
  • 7.6. Latin America Sales Analysis
    • 7.6.1. Overview, Historic and Forecast Sales Analysis
    • 7.6.2. Latin America by Segment Sales Analysis
    • 7.6.3. Latin America by Country Sales Analysis
    • 7.6.4. Brazil Sales Analysis
    • 7.6.5. Argentina Sales Analysis
    • 7.6.6. Peru Sales Analysis
    • 7.6.7. Chile Sales Analysis
    • 7.6.8. Rest of Latin America Sales Analysis
  • 7.7. Middle East & Africa Sales Analysis
    • 7.7.1. Overview, Historic and Forecast Sales Analysis
    • 7.7.2. Middle East & Africa by Segment Sales Analysis
    • 7.7.3. Middle East & Africa by Country Sales Analysis
    • 7.7.4. Saudi Arabia Sales Analysis
    • 7.7.5. UAE Sales Analysis
    • 7.7.6. Israel Sales Analysis
    • 7.7.7. South Africa Sales Analysis
    • 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE IDIOPATHIC THROMBOCYTOPENIC PURPURA THERAPEUTICS COMPANIES

  • 8.1. Idiopathic Thrombocytopenic Purpura Therapeutics Market Competition
  • 8.2. Partnership/Collaboration/Agreement
  • 8.3. Merger And Acquisitions
  • 8.4. New Product Launch
  • 8.5. Other Developments

9 . COMPANY PROFILES OF IDIOPATHIC THROMBOCYTOPENIC PURPURA THERAPEUTICS INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Market Concentration Rate
  • 9.3. Hoffman-L Roche
    • 9.3.1. Company Overview
    • 9.3.2. Company Revenue
    • 9.3.3. Products
    • 9.3.4. Recent Developments
  • 9.4. Amgen Inc
    • 9.4.1. Company Overview
    • 9.4.2. Company Revenue
    • 9.4.3. Products
    • 9.4.4. Recent Developments
  • 9.5. Grifols Biologicals Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Company Revenue
    • 9.5.3. Products
    • 9.5.4. Recent Developments
  • 9.6. GlaxoSmithKline Plc.
    • 9.6.1. Company Overview
    • 9.6.2. Company Revenue
    • 9.6.3. Products
    • 9.6.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Product (USD MN)
  • Corticosteroids Market Sales by Geography (USD MN)
  • Intravenous Immunoglobulin Market Sales by Geography (USD MN)
  • Anti-D Immunoglobulin Market Sales by Geography (USD MN)
  • TPO-RA Market Sales by Geography (USD MN)
  • Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Idiopathic Thrombocytopenic Purpura Therapeutics Report
  • Market Research Process
  • Market Research Methodology
  • Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Product
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Product (USD MN)
  • Corticosteroids Market Sales by Geography (USD MN)
  • Intravenous Immunoglobulin Market Sales by Geography (USD MN)
  • Anti-D Immunoglobulin Market Sales by Geography (USD MN)
  • TPO-RA Market Sales by Geography (USD MN)
  • Global Market by Revenue
  • North America Market by Revenue
  • Europe Market by Revenue
  • Asia Pacific Market by Revenue
  • Latin America Market by Revenue
  • Middle East & Africa Market by Revenue
  • Recent Development in Industry
  • Top Companies Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.